Telogen Effluvium Treatment & Management
- Author: Elizabeth CW Hughes, MD; Chief Editor: Dirk M Elston, MD more...
Because acute telogen effluvium is a reactive process, which resolves spontaneously, treatment usually is limited to reassurance. Any reversible cause of hair shedding, such as poor diet, iron deficiency, hypothyroidism, or medication use, should be corrected.
While chronic telogen effluvium is less likely to resolve rapidly, reassurance is appropriate for these patients. Often, the knowledge that the hair loss will not progress to baldness is comforting to the patient. The patient should be encouraged to style the hair in a way that masks any perceived defects in hair density.
While topical minoxidil is not proven to promote recovery of hair in telogen effluvium, this medication has a theoretical benefit and is well tolerated. Patients who are eager to play an active role in their treatment may choose to use minoxidil.
Hair transplantation is not an effective treatment for telogen effluvium.
If an unbalanced diet is believed to be a contributing factor to telogen effluvium, especially in a case of chronic telogen effluvium, consultation with a dietitian may be extremely helpful. The dietary consultation should focus on adequate protein intake, replenishing low iron stores, and obtaining essential nutrients. If the patient takes large doses of vitamin A, this practice should be stopped.
In most cases, the patient is satisfied with an explanation of the cause and expected course of the condition. If a patient is distraught about hair loss, intermittent office visits for reassurance may be necessary.
Sinclair R. Chronic telogen effluvium: a study of 5 patients over 7 years. J Am Acad Dermatol. 2005 Feb. 52(2 Suppl 1):12-6. [Medline].
Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol. 1996 Dec. 35(6):899-906. [Medline].
Perez-Mora N, Goren A, Velasco C, Bermudez F. Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. Dermatol Ther. 2014 May-Jun. 27(3):159-62. [Medline].
Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993 Mar. 129(3):356-63. [Medline].
Cartwright T, Endean N, Porter A. Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol. 2009 May. 160(5):1034-9. [Medline].
Schmidt S, Fischer TW, Chren MM, Strauss BM, Elsner P. Strategies of coping and quality of life in women with alopecia. Br J Dermatol. 2001 May. 144(5):1038-43. [Medline].
Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol. 2004 Sep. 123(3):455-7. [Medline].
Peters EM, Liotiri S, Bodo E, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol. 2007 Dec. 171(6):1872-86. [Medline].
Padovese V, Racalbuto V, Barnabas GA, Morrone A. Operational research on the correlation between skin diseases and HIV infection in Tigray region, Ethiopia. Int J Dermatol. 2015 Oct. 54 (10):1169-74. [Medline].
Barcaui CB, Gonçalves da Silva AM, Sotto MN, Genser B. Stem cell apoptosis in HIV-1 alopecia. J Cutan Pathol. 2006 Oct. 33(10):667-71. [Medline].
Freinkel RK, Freinkel N. Hair growth and alopecia in hypothyroidism. Arch Dermatol. 1972 Sep. 106(3):349-52. [Medline].
Goette DK, Odom RB. Alopecia in crash dieters. JAMA. 1976 Jun 14. 235(24):2622-3. [Medline].
Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003 Nov. 121(5):985-8. [Medline].
Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006 May. 54(5):824-44. [Medline].
Malkud S. A Hospital-based Study to Determine Causes of Diffuse Hair Loss in Women. J Clin Diagn Res. 2015 Aug. 9 (8):WC01-4. [Medline].
Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol. 2010 Dec. 63(6):991-9. [Medline].
Brodin MB. Drug-related alopecia. Dermatol Clin. 1987 Jul. 5(3):571-9. [Medline].
Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA. 1997 Oct 8. 278(14):1176-8. [Medline].
Katz KA, Cotsarelis G, Gupta R, Seykora JT. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease. J Am Acad Dermatol. 2006 Nov. 55(5 Suppl):S103-4. [Medline].
Tosti A, Piraccini BM, van Neste DJ. Telogen effluvium after allergic contact dermatitis of the scalp. Arch Dermatol. 2001 Feb. 137(2):187-90. [Medline].
Sinclair R, Jolley D, Mallari R, Magee J. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol. 2004 Aug. 51(2):189-99. [Medline].
Rebora A, Guarrera M, Baldari M, Vecchio F. Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient: a simple noninvasive method. Arch Dermatol. 2005 Oct. 141(10):1243-5. [Medline].
Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006 Nov. 55(5):799-806. [Medline].